All articles by Adam Zamecnik

Adam Zamecnik


Adam Zamecnik is a healthcare reporter for Pharmaceutical Technology. He has covered diverse topics such as continuous drug manufacturing, genomic research and sexual health. He is particularly interested in new technologies, health inequality, and cell and gene therapy research.

How can smaller biotechs navigate the landscape of oncology trials?

An upcoming two-day event will host talks on the impact of new technology on oncology trials and smaller biotechs.

How gene therapies can transform sickle cell disease treatment

The potential for using gene therapies to treat sickle cell disease is high, but their durability and high price point invite scrutiny.

CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar

Regulatory applications in EU and the UK will follow a potential filing in the US in early 2024.

Kinnate Biopharma announces 70% layoffs and pipeline restructuring

The company will suspend the development of three assets, considering strategic alternatives for two clinical programmes.

How pharma wants to break the efficacy ceiling in IBD

Despite major shifts in the IBD landscape, most approaches that go beyond targeting inflammation remain in the earlier stages of development.

SparingVision shares trial updates for rare eye disease gene therapies

The company is also planning to expand its Phase I/II PRODYGY lead candidate trial in retinitis pigmentosa to three more US sites.

Avalo drops three rare disease assets amid ongoing challenges

The company will divest the AVTX-800 rare disease compound series to AUG Therapeutics, with an expected completion in Q4 2023.

Verona Pharma’s ensifentrine inches closer to approval decision in COPD

The agency has set a PDUFA target action date of June 2024, with no current plans for an advisory meeting in the works.

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.

UK rejoins EU’s Horizon Europe science programme

The country returns to the EU’s research programme after a Brexit-related absence and questions surrounding its re-entry prospects.